Clinicopathological Features, Diagnoses and Treatments of 6 458 Lung Cancer Patients

LI Lei, LIU Dan, ZHANG Li. et al

Abstract

Lung cancer is the leading cause of cancer-related death on a global scale. This study aimed to review the clinicopathological featuresof primary lung cancer and the practice in diagnoses and treatments. Methods Medical record of patients diagnosed with primary lung cancer in West China Hospital of Sichuan University from 2008 to 2014 were retrospectively reviewed. Clinical characteristics of the patients, including pathological type, age, gender, and TNM stage were analyzed. Results A total of 6 458 patients were diagnosed with primary lung cancer, with male patients comprising the majority (male: 66.5%, n=4 291 vs. female: 33.5%, n=2 167). The patients had an average age of 59.22 yr., mostly (61.1%) between 50 and 70 yr. and 5.1% (n=335) under 40 yr.. More than half (53.3%) of the patients were at stage Ⅳ at diagnosis, compared with 10.5% at stage Ⅰ. The most common histological type was adenocarcinoma（ADC, n=3 523, 54.44%), followed by squamous cell carcinoma (SCC,n=1 637, 25.35%) and small cell lung cancer (SCLC,n=916, 14.18%). The majority of patients were confirmed with fibrobronchoscopy and surgery, and treated with surgery and chemotherapy.Conclusion Patients diagnosed with primary lung cancer in West China Hospital of Sichuan University are primarily elderly men. Adenocarcinoma is the main type. Fibrobronchoscopyis the main method for diagnosis, and chemotherapy and surgery are the main treatments for lung cancer.

 

Keywords: Lung neoplasm, Clinical epidemiology, Histologic type, Diagnosis and treatments 

 

Full Text:

PDF


References


TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012. CA Cancer J Clin,2015,65(2) :87-108. CHEN W, ZHENG R, BAADE PD, etui. Cancer statistics in China, 2015. CA Cancer J Clin,2016,66(2): 115-132. SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2015. CA Cancer J Clin,2015,65( 1) :5-29.

SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2016. CA Cancer J Clin,2016,66( 1):7-30.

ZHANG R, ZHANG Y, WEN F, et al. Analysis of pathological types and clinical epidemiology of 6,058 patients with lung cancer. Chin J Lung Cancer,2016 ,19(3); 129-135.

PINEROS M, SIERRA MS, FORMAN D. Descriptive epidemiology of lung cancer and current status of tobacco control measures in Central and South America. Cancer Epidemiol,2016,44(Suppl 1) :S90-S99.

STRAND ТЕ, MALAYERI С, ESKONSIPO PK. et al. Adolescent smoking and trends in lung cancer incidence among young adults in Norway 1954-1998. Cancer Causes Control,2004,15(1):27-33.

SUBRAMANIAN J, MORGENSZTERN D, GOODGAME B. et al. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young; a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol, 2010, 5 (1): 23-28.

WANG Y, CHEN J, DING W, et al. Clinical features and gene mutations of lung cancer patients 30 years of age or younger. PLoS One, 2015, 10 ( 9 ): e0136659 [2016-11-21 ]. http;//dx. doi. org/10. 1371/journal, pone. 0136659.

HSU CL, CHEN KY, SHIH JY, etal. Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors. BMC Cancer,2012,12; 241 [ 2016-11-21 ]. http://bmccancer. biomedcentral. com/ articles/10. 1186/1471-2407-12-241. doi; 10. 1186/1471- 2407-12-241.

TAKEUCHI Y, SHINAGAWA N, KIKUCHI E, etal. The predictive value of endobronchial ultrasonography with a guide sheath in the diagnosis of the histologic subtypes of lung cancer. Respir Investig,2016 ,54(6) ;473-478.

KANG HK. UM SW, JEONG BH, et al. The utility of endobronchial ultrasound-guided transbronchial needle aspiration in patients with small-cell lung cancer. Intern Med,2016,55(9):1061-1066.

TAVERNER J, CHEANG MY. ANTIPPA P. el al. Negative EBUS-TBNA predicts very low prevalence of mediastinal disease in staging of non-small cell lung cancer. J Bronchology Interv Pulmonol,2016,23(2); 177-180.

GUISIER F, SALAUN M, LACHKAR S, el at. Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS. Respirology, 2016, 21 ( 4 ): 718-726.

WANG Y. TIAN PW, WANG WY, el at. Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture- based next-generation sequencing. Oncotarget, 2016, 7 (40); 65208-65217.

GAO Y. ZHU Y, ZHANG Z. et al. Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in siiuhybridization. J Exp Clin Cancer Res, 2016, 35: 66 [2016-11- 213. http://jeccr. biomedcentral. com/articles/10. 1186/ si3046-016-0340-0. doi; 10. 1186/sl3046-016-0340-0.

NEWMAN AM. BRATMAN SV, TO J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med,2014 ,20(5):548-554.

NEWMAN AM, LOVEJOY AF, К LASS DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol, 2016, 34 ( 5 ) ; 547- 555.

SHARMASV, BELL DW. SETTLEMAN J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer,2007,7(3): 169-181.

TAKEUCHIK, CHOI YL. SODA M. et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res,2008,14(20);6618-6624.

LYNCH TJ, BELL DW, SORDELLA R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med.2004,350(21);2129-2139.

РАО W, MILLER V, ZAKOWSKI M, et al. EOF receptor gene mutations are common in lung cancers from ”never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A, 2004, 101 (36):13306-13311.

MILLER VA» HIRSH V. CADRANEL J, et al. Afatinib versus placebo for patients with advanced, metastatic non- small-cell lung cancer after failure of erlotinib. gefitinib. or both, and one or two lines of chemotherapy (LUX-Lung 1) :a phase 2b/3 randomised trial. Lancet Oncol,2012,13(5) ;528- 538.

JANNE PA, YANG JC, KIM DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med,2015,372(18):1689-1699.

CAMIDGE DR, BANG YJ. KWAK EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small- cell lung cancer:updated results from a phase 1 study. Lancet Oncol,2012,13(10): 1011-1019.

FRIBOULET L, LI N, KATAYAMA R. et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov,2014 ,4(6) ;662-673.

GAINOR JF, SHERMAN CA, WILLOUGHBY K, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol, 2015,10( 2): 232-236.


Refbacks

  • There are currently no refbacks.